ArticleThoracic research and practice2025
Scoring Pulmonary Fibrosis Following COVID-19 Pneumonia with Quantitative HRCT: Relationship with Clinical Parameters, Mean Platelet Volume and Lymphocyte/Monocyte Ratio
Article in Thoracic research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on Long-Term Pulmonary Sequelae Following Severe COVID-19: Reflections on Study Design and Interpretation.Annals of the American Thoracic Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOur study aims to quantify post-Coronavirus disease-2019 (COVID-19) pneumonia-related pulmonary fibrosis using high resolution computed tomography (HRCT) scoring and assess its correlation with clinical parameters, lymphocytes, mean platelet volume (MPV), and lymphocyte/monocyte ratio (LMR). Early detection and understanding of fibrosis progression in patient subsets are essential for enhancing post-COVID-19 patient outcomes. MATERIAL AND
methodsThis retrospective, single-center study aims to quantify post-COVID-19 pneumonia pulmonary fibrosis using HRCT scoring and explore its associations with clinical parameters, lymphocytes, MPV, and LMR. From March 1, 2020, to December 31, 2021, HRCT reports of patients diagnosed with COVID-19 within 14 days of symptom onset were reviewed. Those with COVID-19 pneumonia were identified, and subsequent HRCTs performed 2 months or later post-infection were analyzed for fibrosis. Data on demographics, hospitalization details, and laboratory findings were collected. Fibrosis scores were determined using quantitative HRCT.
resultsA total of 133 patients (60.2% male, mean age 57.3) were included. Of these patients, 50.4% were hospitalized. Quantitative HRCT analysis indicated average fibrosis of 2.7% (range: 0.9-28.7%). Lower lymphocyte counts correlated significantly with increased fibrosis (
conclusionThis study underscores the importance of monitoring lymphocyte counts in COVID-19 patients for early detection of pulmonary fibrosis. The findings suggest a need for screening and prompt diagnosis of fibrosis post-COVID-19, particularly in patients with lymphopenia. Further research using quantitative HRCT could enhance understanding and management of progressive interstitial lung diseases, especially in the context of future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.